State Street Corp Acquires 157,738 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

State Street Corp lifted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 6.8% in the 3rd quarter, Holdings Channel reports. The firm owned 2,471,215 shares of the biopharmaceutical company’s stock after buying an additional 157,738 shares during the quarter. State Street Corp’s holdings in Lexicon Pharmaceuticals were worth $3,880,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. CVI Holdings LLC acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at approximately $34,000. Principal Financial Group Inc. grew its position in Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares in the last quarter. Great Point Partners LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $50,000. BNP Paribas Financial Markets boosted its stake in Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 13,246 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 44.5% during the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 13,972 shares during the period. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Stock Down 7.0 %

Shares of NASDAQ LXRX opened at $0.72 on Tuesday. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The company has a market cap of $177.19 million, a price-to-earnings ratio of -0.96 and a beta of 1.07. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.62 and a 12-month high of $3.73. The firm’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.52.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The company had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same period in the prior year, the business earned ($0.21) EPS. On average, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LXRX has been the subject of several recent research reports. Leerink Partners set a $6.00 price target on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research report on Friday, October 18th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, December 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.